Sustainable

business

solutions

NOLATO GOES GREEN

Sustainable and Renewable packaging materials

Sustainability has always been an integral part of the strategy for the Nolato group. Our aim is to be in the lead and we are constantly seeking new sustainable business solutions and to contribute to a better environment. Nolato is now introducing bio-based Polyet-hylene packaging produced from sugarcane – renewable, sustainable and ECO friendly!

Several product ranges from Nolato Jaycare and Nolato Cerbo have been validated with the alternative “green” Polyethylene and all product properties - mechanical, functional, recycling - are identical to those of petrochemical resins. 
The difference is in the carbon footprint, which is significantly lower for bioplastics in comparison with oil based raw materials.
Contact us and we will show you our new Green product alternatives to you.

Product Performance

PROPERTY

REQUIREMENT IN STANDARD1)

NORMAL POLYMER

SUSTAINABLE POLYMER

Tightness WVP2)avg

Tightness WVPmax

Light transmission3)

30 mg/day/L 
20 mg/day/L 
<10% for 290-450 nm

<3

<4

<10

<3

<4

<10

Notes:

1) According to USP 671 standards

2) Tightness - average values of Cerbo Classic 200ml with SC Light 42 cap and Cerbo Threasy

3) Light transmission - average values of Cerbo Classic (200ml) and Cerbo Threasy bottles

For further information, contact:
E-mail: nolatocerbo@nolato.com /  www.nolato.com/pharma-packaging

Go to article: Home | Under the microscopeGo to article: In this issueGo to article: SHL Medical Company InsightGo to article: SHL MedicalGo to article: ContentsGo to article: MimotopesGo to article: NewsGo to article: VEGA AustraliaGo to article: Covid-19 executive briefing by GlobalDataGo to article: WipotecGo to article: Nasal spray vaccine for Covid-19Go to article: Datwyler Company Insight Go to article: DatwylerGo to article: Covid-19 clinical trials continue to rise in BrazilGo to article: BiogazelleGo to article: AstraZeneca’s Phase I / II Covid-19 vaccine trial Go to article: SwiftpakGo to article: MTPA resumes screening and enrolment for global Phase III clinical trial of MT-1Go to article: Biesterfeld Go to article: The pharma industry briefingGo to article: From antitoxins to Covid-19 drugs: charting the history of antibody drugsGo to article: Quality control: pharma manufacturing inspections explainedGo to article: Molnár-Institute Company InsightGo to article: Molnar-InstituteGo to article: Oxytocin: the therapeutic potential of the ‘love hormone’Go to article: AI-enabled risk detection in pharma manufacturingGo to article: Dr. Paul LohmannGo to article: Addressing the long-term effects of Covid-19Go to article: Eyes on the prize: the latest in retinitis pigmentosa gene therapiesGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: Breaking the taboo: disrupting the fertility sectorGo to article: Neutralising the gluten threat: are we on the cusp of a coeliac disease breakthrough? Go to article: Nolato Company Insight Go to article: NolatoGo to article: Pharmacovigilance case intake: why the hesitation to automate?Go to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Zenatek Go to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue